Biogen, the Massachusetts-based biotechnology heavyweight, made headlines on March 31, 2026, with the announcement of its $5.6 billion acquisition of Apellis Pharmaceuticals. The move marks a significant step in Biogen’s efforts to diversify beyond its traditional neurology focus, venturing deeper into immunology and rare-disease medicines. The all-cash deal, which values Apellis shares at $41 each, is expected to close in the second quarter of 2026, pending customary approvals.
For Biogen, the acquisition is more than a financial transaction—it’s a strategic play designed to secure near-term sales drivers and set the stage for future ambitions, especially in kidney diseases. According to Biogen’s press release and coverage from Dow Jones & Company, the deal grants Biogen access to two of Apellis’ high-profile, FDA-approved medications: Syfovre, for the eye condition geographic atrophy (GA), and Empaveli, used in treating rare kidney diseases such as complement 3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). Empaveli was first approved in the U.S. in 2021 for paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder.
These two marketed products generated a combined $689 million in sales last year, with Syfovre alone accounting for $587 million in GA sales in 2025. The U.S. market for Syfovre is substantial, encompassing roughly 1.5 million patients, yet remains underpenetrated—a tantalizing opportunity for Biogen’s commercial teams. Adam Keeney, Biogen’s executive vice president and head of corporate development, voiced optimism about the potential, stating, “We know that the market is competitive, but we’re also optimistic that best-in-class Syfovre, coupled with Biogen’s demonstrated U.S. capabilities and Apellis’ sales and marketing team, we can enable the product to realize its full potential.”
Syfovre faces stiff competition from Astellas’ Izervay, which was first cleared by the FDA in 2023 and received a label expansion last year. Still, Biogen is betting that its commercial reach and experience, combined with Apellis’ existing sales infrastructure, will give Syfovre an edge in this burgeoning market.
Empaveli, meanwhile, is still in the early days of its launch for its two new kidney indications. Biogen sees Empaveli not just as a revenue generator but also as a commercial “anchor” for its broader nephrology ambitions. CEO Chris Viehbacher underscored this point, noting that Empaveli could help lay the foundation for the launch of Biogen’s late-stage candidate felzartamab, which is currently in phase 3 trials for three kidney disease indications: antibody-mediated rejection, immunoglobulin A nephropathy, and primary membranous nephropathy. The first phase 3 readout for felzartamab is expected in the first half of 2027.
“This is really an immunology play,” Viehbacher explained to analysts, as reported by Fierce Pharma. He added that with the planned acquisition of Apellis, Biogen is likely finished with significant M&A moves for the present. Viehbacher also acknowledged the importance of near-term revenue, stating that Biogen didn’t “want to take a lot of phase 3 risk,” and instead sought a company with products either early in their launch or about to hit the market. “We didn’t want to stretch our balance sheet with a transaction either and wanted to find a target that we could acquire at a favorable price,” he said.
Under the terms of the agreement, Apellis investors will receive a contingent value right (CVR) for each share held, worth up to $4 per share if certain sales thresholds for Apellis’ products are met. This sweetener appears to have been well-received by Apellis shareholders; following the announcement, Apellis shares more than doubled, while Biogen’s own stock slipped by 4% by midmorning—a sign that the market is still digesting the implications of the deal. Adam Keeney noted, “It will probably take some time for analysts to wrap their heads around the story.”
The acquisition also has implications for personnel and partnerships. Apellis, headquartered in Waltham, Massachusetts, employs around 740 people. Biogen expects a “significant portion” of these staffers to join its ranks, helping to smooth the integration and maintain momentum behind the acquired products. Additionally, Biogen will continue to work with Apellis’ partner, Sobi, on the commercialization of Empaveli outside the United States, ensuring continuity for patients and partners abroad.
Financially, the acquisition comes at a pivotal moment for Biogen. The company reported a 2% increase in sales to $9.9 billion in 2025—the first annual sales uptick since 2019, according to Fierce Pharma. However, Biogen has forecast a mid-single-digit decline in 2026, with projected sales falling to between $9.3 billion and $9.5 billion. The addition of Apellis’ revenue streams is expected to provide a buffer during this period of transition. Robin Kramer, Biogen’s chief financial officer, told analysts that revenue from Syfovre and Empaveli is expected to grow in the mid- to high teens annually “for at least the next two years.” Kramer also indicated that Biogen will adjust its 2026 guidance when it reports first-quarter earnings later this year.
Looking further ahead, Biogen’s late-stage pipeline remains robust, with phase 3 assets across neurology and immunology. But major launches from these programs aren’t expected to begin contributing to growth until around 2028. In the meantime, the Apellis acquisition is designed to fill the gap, providing near-term sales momentum and anchoring Biogen’s ambitions in immunology and nephrology.
Despite the clear strategic rationale, the market’s initial reaction was mixed. While Apellis shareholders cheered the deal, Biogen investors appeared more cautious, perhaps reflecting concerns about integration risks, competitive pressures, and the time needed for the acquired assets to reach their full potential. Still, Biogen’s leadership remains confident. Viehbacher summed up the company’s position, stating he feels “great” about Biogen’s late-stage pipeline but acknowledged the need for nearer-term growth drivers as the company navigates the next few years.
As the biotech sector continues to evolve, Biogen’s bold move to acquire Apellis underscores the high stakes and complex calculations involved in pharmaceutical M&A. With blockbuster ambitions for Syfovre and Empaveli, and eyes set firmly on the future of kidney disease treatments, Biogen is betting big on immunology to drive its next chapter—even if the market needs a little time to catch up.